A rising population and an expanding immunization schedule makes China an attractive prospect for vaccine manufacturers, and now the largest vaccine manufacturer of them all, GlaxoSmithKline (GSK), is eyeing up the potential for a joint venture in the country.
"We are keen to find a partner in China," Christophe Weber, head of the company's vaccines unit, told Bloomberg. Over the next 10 years, "the Chinese government will progressively upgrade its immunization calendar, and we want to be there and to be a partner when that happens."
The company is reportedly in discussions to form a joint venture with a Chinese company. The move will expand Glaxo's operations in emerging markets, where sales are estimated to be double that in the US or Europe in 10 years time. Glaxo already have similar joint venture partnerships in Japan with Daiichi Sankyo Co and India with Biological E.
Read more about this story at Bloomberg >
If you want to know more about strategy and innovation in vaccines, you might be interested in attending the World Vaccine Congress Europe 2013, 16-17 October 2013, Lille.